Integrin antagonists useful as anticancer agents
US8003806B2 · kind B2 · utility
11Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2005 |
| Grant date | Aug 23, 2011 |
| Priority date | — |
| Expiry date | Nov 9, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to compounds of the Formula 1and to pharmaceutically acceptable salts and solvates thereof, wherein A, X2, X4, X5 and X1 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula 1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.